| pegylated liposomal doxorubicin / Generic mfg. |
NCT00004197: Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | | US | keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy, cyclophosphamide, Cytoxan, doxorubicin hydrochloride, Lipodox, Lipodox 50, and Doxil, mitoxantrone hydrochloride, Novantrone, prednisone, Prednisone Intensol, Deltasone, Rayos, vincristine sulfate, Kyocristine, Vincrisul, Onkovin | University of Nebraska, National Cancer Institute (NCI) | Lymphoma | 01/02 | 11/03 | | |
NCT00003388: Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma |
|
|
| Completed | 2 | 38 | US | filgrastim, cyclophosphamide, cytarabine, methotrexate, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) | Lymphoma | 04/03 | | | |
NCT00003493: Combination Chemotherapy in Treating Patients With Multiple Myeloma |
|
|
| Completed | 2 | | US | dexamethasone, pegylated liposomal doxorubicin hydrochloride, vincristine sulfate | The Cleveland Clinic | Multiple Myeloma and Plasma Cell Neoplasm | | 04/04 | | |
NCT00183976: Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas |
|
|
| Terminated | 2 | 15 | US | Pegylated Liposomal Doxorubicin (Doxil) and Rituximab | University of Southern California | Non-Hodgkin's Lymphoma, Burkitt Lymphoma, Primary Effusion Lymphomas | 09/05 | 01/06 | | |
NCT00201695: Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma |
|
|
| Completed | 2 | 12 | US | Doxil®, Doxorubicin HCL liposome injection, Vincristine, Oncovin, Dexamethasone, DVd, Arsenic Trioxide, Trisenox, ATO | Ohio State University Comprehensive Cancer Center | Multiple Myeloma | 09/06 | 08/08 | | |
| Completed | 2 | 40 | US | Velcade, Doxil, Dexamethasone | University of Michigan Rogel Cancer Center | Multiple Myeloma | 01/07 | 12/07 | | |
NCT00561743: A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients |
|
|
| Completed | 2 | 50 | US | Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone | Janssen-Ortho Inc., Canada | Multiple Myeloma | 05/07 | 05/07 | | |
NCT00337194: SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Completed | 2 | 30 | US | monoclonal antibody SGN-30, SGN-30, placebo, PLCB, vinorelbine tartrate, Eunades, navelbine ditartrate, NVB, VNB, pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, LipoDox, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma | 09/08 | 10/14 | | |
NCT00222105: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life |
|
|
| Completed | 2 | 25 | NA | Doxil, pegylated liposomal doxorubicin, Thalidomide, thalidomid, Dexamethasone, decadron | University of Kansas Medical Center, Ortho Biotech, Inc. | Multiple Myeloma | 04/09 | 07/09 | | |
NCT00074087 / 2004-001746-32: Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides |
|
|
| Completed | 2 | 49 | Europe, RoW | pegylated liposomal doxorubicin hydrochloride | European Organisation for Research and Treatment of Cancer - EORTC | Lymphoma | 07/09 | 09/10 | | |
NCT00706953: A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib |
|
|
| Withdrawn | 2 | 0 | US | bortezomib; pegylated liposomal doxorubicin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Centocor Ortho Biotech Services, L.L.C. | Multiple Myeloma | 06/10 | 06/10 | | |
NCT00837200: Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies |
|
|
| Terminated | 2 | 13 | US | Oncaspar, Doxil, Decadron, PEG-asparaginase, PEG-liposomal doxorubicin | Milton S. Hershey Medical Center | Non-hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma | 01/11 | 10/13 | | |
NCT00148317: Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma |
|
|
| Completed | 2 | 38 | US | Bortezomib, velcade, dexamethasone, decadron, liposomal doxorubicin, cyclophoshamide, cytoxan, filgrastim, neupogen | Weill Medical College of Cornell University, Millennium Pharmaceuticals, Inc. | Multiple Myeloma | 02/11 | 11/12 | | |
NCT00366106: Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma |
|
|
| Terminated | 2 | 32 | US | bortezomib, Velcade, dexamethasone, Decadron, doxorubicin HCl liposome, Doxil | Accelerated Community Oncology Research Network, Millennium Pharmaceuticals, Inc. | Multiple Myeloma | 03/11 | 03/11 | | |
NCT00458705: Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma |
|
|
| Completed | 2 | 45 | US | bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride, thalidomide | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Multiple Myeloma and Plasma Cell Neoplasm | 04/11 | 04/11 | | |
NCT00523848: Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma |
|
|
| Completed | 2 | 46 | US | bortezomib, pegylated liposomal doxorubicin hydrochloride, thalidomide | Roswell Park Cancer Institute | Multiple Myeloma and Plasma Cell Neoplasm | 09/11 | 10/12 | | |
NCT00389818: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | 43 | US | filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, immunohistochemistry staining method, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC | Lymphoma | 09/11 | 09/11 | | |
|
NCT00851552: Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment |
|
|
| Terminated | 2 | 9 | US | rituximab, bortezomib, pegylated liposomal doxorubicin hydrochloride, gene expression analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, flow cytometry, laboratory biomarker analysis | Roswell Park Cancer Institute, Ortho Biotech, Inc. | Lymphoma | 09/11 | 09/11 | | |
NCT01160484: Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma |
|
|
| Completed | 2 | 40 | US | DVD-R, Decadron, Velcade, Doxil, Revlimid | Oncotherapeutics, Celgene Corporation | Multiple Myeloma | 12/11 | 09/12 | | |
|
NCT00184002: Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas |
|
|
| Completed | 2 | 68 | US | Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone | University of Southern California, Ortho Biotech, Inc. | Non-Hodgkin's Lymphoma | 12/12 | 05/13 | | |
NCT00617591: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) |
|
|
| Completed | 2 | 57 | US | Lenalidomide, Revlimid®, Pegylated Liposomal Doxorubicin (PLD), Doxil®, Dexamethasone, Decadron® | H. Lee Moffitt Cancer Center and Research Institute, Celgene Corporation, Ortho Biotech Clinical Affairs, L.L.C. | Multiple Myeloma | 04/13 | 04/13 | | |
NCT01078441: Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant |
|
|
| Terminated | 2 | 2 | US | liposomal doxorubicin, Doxil, Doxorubicin HCl Liposomal, Doxorubicin Hydrochloride Liposomal, Doxorubicin Hydrochloride Liposome, bortezomib, Velcade, PS-341, MLN-341, LDP-341, dexamethasone, Decadron, Hexadrol, Dexameth, Dexone, DXM, cyclophosphamide, CTX, Cytoxan, Neosar | National Cancer Institute (NCI) | Refractory Multiple Myeloma | 02/14 | 03/14 | | |
NCT01492881: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Withdrawn | 2 | 0 | US | Vorinostat, Zolina, Bortezomib, Velcade, pegylated liposomal doxorubicin, Doxil | UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Multiple Myeloma | 01/15 | 01/17 | | |
MYLY, NCT01848652: Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine. |
|
|
| Terminated | 2 | 5 | Europe | infusion of MYOCET | University Hospital, Brest, Teva Pharmaceuticals USA | Cerebral Lymphoma B Cell Refractory | 05/15 | 05/15 | | |
NCT00074490: Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers |
|
|
| Terminated | 2 | 442 | US | Rituximab, Rituxan, Fludarabine, Fludara, Etoposide, Toposar, Doxorubicin, Doxil, Vincristine, Leurocristine, Cyclophosphamide, Cytoxan, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Deltasone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, Neupogen, T-Rapa cell Donor Lymphocyte Infusion (DLI) | National Cancer Institute (NCI) | Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome | 07/17 | 08/17 | | |
|
NCT00255801: Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma |
|
|
| Completed | 2 | 37 | US | Targretin® (bexarotene), pegylated liposomal doxorubicin hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Tibotec Pharmaceutical Limited, M.D. Anderson Cancer Center, NYU Langone Health, Hackensack Meridian Health, Roswell Park Cancer Institute | Lymphoma | 10/17 | 10/17 | | |
NCT00237627: Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 107 | US | PS-341, Doxil, pegylated liposomal doxorubicin, Velcade, Bortezomib | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 12/06 | 01/10 | | |
NCT00006029: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma |
|
|
| Completed | 1/2 | 91 | US | gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, vinorelbine tartrate | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Lymphoma | 02/07 | 02/07 | | |
NCT00244985: Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Completed | 1/2 | 42 | US | rituximab, pegylated liposomal doxorubicin hydrochloride | Roswell Park Cancer Institute, Ortho Biotech, Inc. | Lymphoma | 08/08 | 12/12 | | |
NCT00724568: Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma |
|
|
| Completed | 1/2 | 74 | US, Canada | Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Doxil | University of Michigan Rogel Cancer Center | Multiple Myeloma | 04/09 | 09/14 | | |
NCT00516191: A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma |
|
|
| Withdrawn | 1/2 | 0 | US | Liposomal Doxorubicin/Melphalan/Bortezomib, Liposomal Doxorubicin=Doxil, Melphalan=Alkeran, Bortezomib=Velcade | University of California, San Francisco | Multiple Myeloma | 10/10 | 12/10 | | |
NCT00849251: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma |
|
|
| Terminated | 1/2 | 31 | US | cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, LipoDox, bortezomib, LDP 341, MLN341, VELCADE, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM | University of Washington, National Cancer Institute (NCI) | Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma | 12/11 | 06/15 | | |
NCT00750815: Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) |
|
|
| Completed | 1/2 | 58 | US | Cyclophosphamide, Cytoxan, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD), VELCADE, DOXIL®, PLD, CVDD, VDD | H. Lee Moffitt Cancer Center and Research Institute, Millennium Pharmaceuticals, Inc., Ortho Biotech, Inc. | Multiple Myeloma | 12/12 | 05/13 | | |
NCT01177683: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma |
|
|
| Terminated | 1/2 | 32 | US | Bendamustine, Doxorubicin, Bortezomib, Filgrastim | Sherif Farag, MB, BS, Hoosier Cancer Research Network, Cephalon, Inc. | Multiple Myeloma | 12/17 | 12/17 | | |
NCT01246063: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Completed | 1/2 | 40 | US | carfilzomib, Kyprolis, CFZ, pegylated liposomal doxorubicin (PLD), DOXIL, Dexamethasone, Decadron | Washington University School of Medicine | Multiple Myeloma | 12/17 | 03/18 | | |
